Medical device developer Boston Scientific ( BSX) said it received clearance from the Food and Drug Administration to market its saphenous vein graft, or SVG, disease treatment.

The company's FilterWire EX Embolic Protection System will be launched next week in the U.S. SVG disease occurs when saphenous veins harvested from the leg for use in coronary artery bypass graft surgery develop atherosclerosis.

Shares of the company were up 0.7% at $56.43 in late morning trading Monday.

If you liked this article you might like

Hot Topic's Relief Bounce

Hot Topic's Relief Bounce

Limited Brands Profit Jumps

Limited Brands Profit Jumps

Glitch Lingers at Ross Stores

Glitch Lingers at Ross Stores

Dillard's Halves Loss

Dillard's Halves Loss

Do-It-Yourself Boost for Economy

Do-It-Yourself Boost for Economy